@entity2675 is rare. Median age at diagnosis is approximately 65 years, and > 35% of @entity2675 occur in elderly @entity1 . Retroareolar lump is the most frequent symptom, and 25-30% of @entity5 are T(4) lesions. @entity513 represents almost 90% of the cases, and 10% are @entity513 in situ. Axillary nodal involvement is present in 50-60% of the cases. @entity172 and @entity1420 receptors are positive in 75-92% and 54-77% of the cases. Mastectomy with axillary dissection remains the standard treatment. Sentinel lymph node biopsy could be proposed in small @entity5 (< or = 2 cm). Locoregional radiotherapy is very often indicated. @entity440 is the standard adjuvant treatment, but chemotherapy is proposed in young @entity1 with axillary nodal involvement and/or negative hormone receptors. @entity5 size and, more particularly, histopathological axillary involvement are the strongest predictive factors for both locoregional recurrence and @entity3 . Globally, the prognosis is similar to that in @entity1 (at identical stage), but the intercurrent death rate is higher due to the important impact of comorbidities and second @entity5 .

Strategies in treating XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'men'] @entity172 :: ('MESH:D004967', 'Chemical') :: ['Estrogen'] @entity2675 :: ('MESH:D018567', 'Disease') :: ['Male breast cancer', 'male breast cancers'] @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone'] @entity440 :: ('MESH:D013629', 'Chemical') :: ['Tamoxifen'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Tumour', 'tumours', 'neoplasm'] @entity513 :: ('MESH:D044584', 'Disease') :: ['Infiltrating ductal carcinoma', 'ductal carcinoma'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']
@entity2675 :: (MESH:D018567,Disease) :: ['male breast cancer']
